Shares of Divis Laboratories experienced a decline of 2.59% in today's session, with the stock price falling to Rs 5,744. The stock is a constituent of the NIFTY NEXT 50 index.
Financial Snapshot:
Here's a look at the company's recent financial performance:
Consolidated Quarterly Results:
| Heading | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 2,118.00 Crore | Rs 2,338.00 Crore | Rs 2,319.00 Crore | Rs 2,585.00 Crore | Rs 2,410.00 Crore |
| Net Profit | Rs 430.00 Crore | Rs 510.00 Crore | Rs 589.00 Crore | Rs 662.00 Crore | Rs 545.00 Crore |
| EPS | 16.20 | 19.20 | 22.20 | 24.93 | 20.49 |
The company's revenue for the quarter-ending June 2025 stood at Rs 2,410.00 Crore, compared to Rs 2,585.00 Crore in the quarter-ending March 2025. The net profit for the quarter-ending June 2025 was Rs 545.00 Crore, compared to Rs 662.00 Crore in the previous quarter.
Consolidated Yearly Results:
| Heading | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | Rs 6,969.40 Crore | Rs 8,959.83 Crore | Rs 7,767.51 Crore | Rs 7,845.00 Crore | Rs 9,360.00 Crore |
| Net Profit | Rs 1,984.29 Crore | Rs 2,960.45 Crore | Rs 1,823.38 Crore | Rs 1,600.00 Crore | Rs 2,191.00 Crore |
| EPS | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| BVPS | 350.15 | 441.82 | 480.96 | 512.11 | 564.87 |
| ROE | 21.34 | 25.24 | 14.28 | 11.78 | 14.63 |
| Debt to Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
The company's revenue for the year-ending March 2025 stood at Rs 9,360.00 Crore, compared to Rs 7,845.00 Crore in the year-ending March 2024. The net profit for the year-ending March 2025 was Rs 2,191.00 Crore, compared to Rs 1,600.00 Crore in the previous year. The debt to equity ratio remained at 0.00 for the year-ending March 2025.
Consolidated Yearly Income Statement:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Sales | 9,360 | 7,845 | 7,767 | 8,959 | 6,969 |
| Other Income | 352 | 339 | 344 | 113 | 62 |
| Total Income | 9,712 | 8,184 | 8,112 | 9,073 | 7,031 |
| Total Expenditure | 6,794 | 6,018 | 5,742 | 5,389 | 4,365 |
| EBIT | 2,918 | 2,166 | 2,369 | 3,684 | 2,666 |
| Interest | 2 | 3 | 0 | 0 | 0 |
| Tax | 725 | 563 | 545 | 723 | 681 |
| Net Profit | 2,191 | 1,600 | 1,823 | 2,960 | 1,984 |
Sales increased from 7,845 in March 2024 to 9,360 in March 2025. The net profit also increased from 1,600 in March 2024 to 2,191 in March 2025.
Consolidated Quarterly Income Statement:
| Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | |
|---|---|---|---|---|---|
| Sales | 2,410 | 2,585 | 2,319 | 2,338 | 2,118 |
| Other Income | 119 | 86 | 82 | 106 | 79 |
| Total Income | 2,529 | 2,671 | 2,401 | 2,444 | 2,197 |
| Total Expenditure | 1,793 | 1,806 | 1,675 | 1,721 | 1,593 |
| EBIT | 736 | 865 | 726 | 723 | 604 |
| Interest | 3 | 1 | 0 | 1 | 0 |
| Tax | 188 | 202 | 137 | 212 | 174 |
| Net Profit | 545 | 662 | 589 | 510 | 430 |
Sales decreased from 2,585 in Mar 2025 to 2,410 in June 2025. The net profit also decreased from 662 in March 2025 to 545 in June 2025.
Cash Flow:
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Operating Activities | 1,653 | 1,261 | 2,459 | 1,911 | 1,946 |
| Investing Activities | -804 | -269 | -2,707 | -2,194 | 75 |
| Financing Activities | -799 | -799 | -797 | -532 | -34 |
| Others | 0 | 0 | 0 | 0 | 0 |
| Net Cash Flow | 50 | 193 | -1,045 | -815 | 1,987 |
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | |
|---|---|---|---|---|---|
| Share Capital | 53 | 53 | 53 | 53 | 53 |
| Reserves & Surplus | 14,916 | 13,518 | 12,714 | 11,675 | 9,241 |
| Current Liabilities | 1,452 | 1,278 | 1,101 | 1,195 | 1,112 |
| Other Liabilities | 511 | 621 | 570 | 450 | 367 |
| Total Liabilities | 16,932 | 15,470 | 14,438 | 13,374 | 10,774 |
| Fixed Assets | 6,464 | 5,517 | 4,934 | 4,794 | 4,414 |
| Current Assets | 10,081 | 9,675 | 9,311 | 8,351 | 6,174 |
| Other Assets | 387 | 278 | 192 | 228 | 184 |
| Total Assets | 16,932 | 15,470 | 14,438 | 13,374 | 10,774 |
| Contingent Liabilities | 1,841 | 1,432 | 736 | 1,259 | 1,107 |
| Ratio | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Basic EPS (Rs.) | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| Diluted Eps (Rs.) | 74.75 | 111.52 | 68.69 | 60.27 | 82.53 |
| Book Value [Excl. Reval Reserve]/Share (Rs.) | 350.15 | 441.82 | 480.96 | 512.11 | 564.87 |
| Dividend/Share (Rs.) | 20.00 | 30.00 | 30.00 | 30.00 | 30.00 |
| Face Value | 2 | 2 | 2 | 2 | 2 |
| Gross Profit Margin (%) | 41.93 | 44.59 | 34.92 | 32.42 | 35.47 |
| Operating Margin (%) | 38.26 | 41.12 | 30.50 | 27.60 | 31.17 |
| Net Profit Margin (%) | 28.47 | 33.04 | 23.47 | 20.39 | 23.40 |
| Return on Networth / Equity (%) | 21.34 | 25.24 | 14.28 | 11.78 | 14.63 |
| ROCE (%) | 27.60 | 30.25 | 17.76 | 15.26 | 18.85 |
| Return On Assets (%) | 18.41 | 22.13 | 12.62 | 10.34 | 12.93 |
| Current Ratio (X) | 5.55 | 6.99 | 8.46 | 7.57 | 6.94 |
| Quick Ratio (X) | 3.62 | 4.62 | 5.73 | 5.08 | 4.71 |
| Debt to Equity (x) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratios (X) | 3,065.41 | 4,994.76 | 4,048.48 | 848.00 | 1,660.00 |
| Asset Turnover Ratio (%) | 64.68 | 0.74 | 0.56 | 0.52 | 0.58 |
| Inventory Turnover Ratio (X) | 3.25 | 1.44 | 1.03 | 1.05 | 2.92 |
| 3 Yr CAGR Sales (%) | 33.83 | 34.59 | 20.00 | 6.10 | 2.21 |
| 3 Yr CAGR Net Profit (%) | 50.42 | 47.94 | 15.09 | -10.20 | -13.97 |
| P/E (x) | 48.47 | 39.47 | 41.10 | 57.16 | 69.98 |
| P/B (x) | 10.37 | 9.97 | 5.88 | 6.71 | 10.22 |
| EV/EBITDA (x) | 32.23 | 28.55 | 26.10 | 34.24 | 44.96 |
| P/S (x) | 13.83 | 13.05 | 9.66 | 11.61 | 16.34 |
Divis Laboratories announced a final dividend of Rs 30 per share (1500%) on May 19, 2025, with an effective date of July 25, 2025. The company had also announced a final dividend of Rs 30 per share on May 27, 2024.
The company announced a bonus issue with ratio 1:1 on August 08, 2015, with exbonus date as September 23, 2015.
The company had a stock split on August 03, 2007, with old face value of 10 and new face value of 2.
Moneycontrol analysis on September 19, 2025, indicated a very bullish sentiment for the stock.
With the stock's last traded price at Rs 5,744, Divis Laboratories has experienced a decline of 2.59% in today's session.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
